The Significance of SIX1 as a Prognostic Biomarker for Survival Outcome in Various Cancer Patients: A Systematic Review and Meta-Analysis

Guang Zhu1,2, Ying Liu2, Lei Zhao2, Zhenhua Lin2,3 and Yingshi Piao2,3*

1 Guangdong Provincial Education Department Key Laboratory of Nano-Immunoregulation Tumour Microenvironment, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, China, 2 Tumor Research Center, Medical School of Yanbian University, Key Laboratory of Pathobiology of High Frequency Oncology in Ethnic Minority Areas (Yanbian University), State Ethnic Affairs Commission, Yanji, China, 3 Key Laboratory of Science and Technology Department of Jilin Province, Key Laboratory of Changbai Mountain Natural Medicine of Ministry of Education, Yanbian University, Yanji, China

Sine Oculis Homeobox Homolog 1 (SIX1) is reported to promote cancer initiation and progression in many preclinical models and is demonstrated in human cancer tissues. However, the correlation between SIX1 and cancer patients’ prognosis has not yet been systematically evaluated. Therefore, we performed a systematic review and meta-analysis in various human cancer types and extracted some data from TCGA datasets for further verification and perfection. We constructed 27 studies and estimated the association between SIX1 expression in various cancer patients’ overall survival and verified with TCGA datasets. Twenty-seven studies with 4899 patients are included in the analysis of overall, and disease-free survival, most of them were retrospective. The pooled hazard ratios (HRs) for overall and disease-free survival in high SIX1 expression patients were 1.54 (95% CI: 1.32-1.80, \( P \leq 0.00001 \)) and 1.83 (95% CI: 1.31-2.55, \( P = 0.0004 \)) respectively. On subgroup analysis classified in cancer type, high SIX1 expression was associated with poor overall survival in patients with hepatocellular carcinoma (HR 1.50; 95% CI: 1.17-1.93, \( P = 0.001 \)), breast cancer (HR 1.31; 95% CI: 1.10-1.55, \( P = 0.002 \)) and esophageal squamous cell carcinoma (HR 1.89; 95% CI: 1.42-2.52, \( P = 0.0001 \)). Next, we utilized TCGA online datasets, and the consistent results were verified in various cancer types. SIX1 expression indicated its potential to serve as a cancer biomarker and deliver prognostic information in various cancer patients. More works still need to improve the understandings of SIX1 expression and prognosis in different cancer types.

Keywords: Sine Oculis Homeobox Homolog 1, cancer, meta-analysis, prognosis, TCGA

INTRODUCTION

Cancer is now being predicted as a leading cause of deaths based on the latest global cancer statistic report, there are 24.5 million new cancer diagnoses and 9.6 million deaths each year (1). The features of most cancers are heterogeneous, depends on the treatment response, recurrence, and the cancer metastasis potential. Biomarkers that annotated this different feature in different tumor types
and stages, either independently or involved in the current tumor stages can offer deep understandings and help to guide the best clinical treatment, like radical surgery or chemoradiotherapy. This approach was approved by both follow-up data collections and the statistics obtained by cancer patients’ outcome. However, despite the advantages that cancer biomarkers offered, failures in transforming discoveries into clinical models or lacking prospective biomarker validation to guide clinical treatment properly still troubles cancer experts and clinical treatments.

In the past two decades, many studies demonstrated that sine oculis homeobox 1 (SIX1) serve as a regulator in organ generation and play essential roles both in tumorigenesis and progression (2). In vertebrates, the SIX gene family is characterized by the SIX-type homeodomain (HD, 60 amino acids) and SIX domain (SD, 110-115 amino acids). SIX family genes have been discovered in many kinds of species and is highly conservative. One family member, the SIX homeobox 1 (SIX1), is extensively investigated. SIX1 is reported involving in the development of tissues, like muscle (3), kidney (4), sensory organs (5), and auditory system (6). Recently, much attention was switched to the roles of SIX1 in tumorigenesis. Reports showed that SIX1 participates in various cancers initiation, including hepatocellular carcinoma (7), breast cancer (8), ovarian cancer (9), cervical cancer (10), osteosarcoma (11), colorectal cancer (12), and Wilms tumors (13). Meanwhile, SIX1 has also been verified in promoting cancer progression, accelerating cancer cell metabolism and progression.

Given that the complexity and its various roles play, SIX1 is essential in the initiation and progression of primary cancer to a distant metastasis and finally lead to an untreated late stage (14, 15). However, determining the prognostic benefits of SIX1 expression in cancer patients is unclear. The prognostic role of total SIX family member protein expression had been estimated by two meta-analysis articles in 2016, both was estimated in single cancer type, one was estimated in breast cancer (8), and the other was in lung cancer (16), as new research appeared, we intend to conduct a new meta-analysis and to expound the potential prognostic value of specific SIX1 in depth. To address this issue, we utilized a systematic meta-analysis of SIX1 protein expression in tumor tissues with a variable being high versus low SIX1 expression level. We estimated the correlation between SIX1 expression level and prognosis in multiple cancers. The validation with the The Cancer Genome Atlas (TCGA) online datasets were added for further data perfection and supplementary of this study.

Our aims were to investigate whether SIX1 expression predicts survival outcomes in cancer patients, and whether SIX1 quantization can be considered as a helpful biomarker in various cancers.

MATERIALS AND METHODS

Publication Search

This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) (17). We utilized a systematic search based on the PubMed, Web of Science and Embase database from January 1, 2006, to August 31, 2020, using both keywords. Our search keywords were: ("cancer” OR “tumor” OR “carcinoma”) and ("SIX1” OR “Sine Oculis Homeobox Homolog 1”) and ("prognosis” OR “prognostic” OR “outcome”). References or associated research were reviewed and include as potential articles.

Inclusion and Exclusion Criteria

The articles selection process was done by two doctors (Dr. Lin and Dr. Piao). The included criteria were as follows: (1) reported the correlation of the expression of SIX1 and the survival data of patients; (2) performed the relevant clinicopathological features. The exclusion articles were as follows: (1) studies not based on human; (2) unreachable/insufficient Hazard ratios (HRs); (3) case reports, reviews, or meta-analysis; (4) repetitive patients. Studies on human with solid cancer report and presented the effect of SIX1 on overall survival, and/or disease/recurrence-free survivals were included. Studies were excluded if they published based on duplicated data.

Statistical Analysis

Data was cross-checked by (Dr. Lin and Dr. Piao) independently. In all included studies, the independent variable survey was the SIX1 expression defined as high or low. The natural logarithm and standard error of hazard ratio were gathered for the prognosis in each study. Pooled estimates were performed using forest plots and analyzed by using Review Manager Version 5.3. Heterogeneity was considered high, medium, or low if $I^2$ above 75%, 50-75% or below 50%, respectively (18). Digitizer 4.1 software was used to extract data from the Kaplan-Meier (K-M) plot, if the HRs and its 95% confidence interval (CIs) offered indirectly by the article. In addition, the included studies were all assessed by using the Newcastle-Ottawa Scale (NOS) (19).

Funnel plots were constructed for evaluating the overall and disease-free survival analyses. Subgroup analysis was aimed to perform the correlation between SIX1 expression and the prognosis in various cancers for overall survival. $P$-value<0.05 considered as statistically significant.

Our meta-analysis was based on the Stata 12.0 software (Stata Corporation, College Station, TX, United States) and Review Manager Version 5.3 (Cochrane Collaboration, Oxford, UK). The prognostic value of SIX1 on OS, DFS was performed by pooled HRs and 95% CIs. Besides, odds ratios (ORs) with corresponding 95% CIs were performed to analyze the association between SIX1 and clinicopathological features. Chi square-based Cochran Q test and $I^2$ test were calculated to determine the heterogeneity among these articles. $I^2 > 50\%$ or $P$-value < 0.05 was considered for being a significant heterogeneity and a random-effect model would be used, otherwise, a fixed model will be used. The effect of covariates was evaluated by regression analysis. The sensitivity and publication bias were also performed. $P < 0.05$ was considered statistically significant with two-sides.
Analysis Using TCGA Online Database
Data of SIX1 expression and clinicopathological parameters in TCGA were obtained from the Gene Expression Profiling Interactive Analysis (GEPIA, http://gepia.cancer-pku.cn) (20) and the KM-plotter (http://kmplot.com/analysis/index.php?p=background). To generate the K-M survival analysis and the overall survival plots, SIX1 expression levels were classified into low/median or high. The difference between two groups was conducted by Log-rank test.

Mechanism Prediction of SIX1 and Protein Interaction Network
We obtained the data from STRING database (http://string-db.org/) (21), an online common software, to find SIX1 related genes and to provide an assessment for the protein-protein interactions (PPI) of SIX1 and its related genes.

RESULTS
Search Results
The study flow figure is shown in Figure 1. A total of 27 studies were included in this meta-analysis with a total 4899 patients (Table 1). 27 studies provided overall survival data, 5 among which also reported disease-free survival data. Some other studies failed to report sufficient data and were excluded. 202 articles remained after scanning the titles and abstracts, and among the 202 studies, 109 were experimental studies only, 2 were excluded for review articles, 38 were excluded for no survival data reported, 19 were excluded for insufficient HRs or other data, 2 were excluded because the data is no longer available, and 5 analysis was based on TCGA data base. Finally, 27 eligible studies were including in this meta-analysis (22–48). These eligible researches contained 4899 patients, involved 12 types of cancers, including the hepatocellular carcinoma (n=3), colorectal cancer (n=2), breast cancer (n=10), esophageal squamous cell carcinoma (n=3), gastric cancer (n=3), pancreatic cancer (n=1), lung adenocarcinoma (n=1), osteosarcoma (n=1), melanoma (n=1), prostate cancer (n=1), and glioma (n=1). In these studies, SIX1 expression levels were estimated by qPCR or immunohistochemistry (IHC). The characteristics of the articles were listed in Table 1.

Study Demographics
The demographics of the included studies were listed in Table 1. There are 3 studies in hepatocellular carcinoma (410 patients), 2 studies in colorectal cancer (1065 patients), 10 studies in breast cancer (1645 patients), 3 studies in esophageal squamous carcinoma (471 patients), 3 studies in gastric cancer (411 patients). One each study for other six cancer types: pancreatic ductal cancer (148 patients), lung adenocarcinoma (64 patients), osteosarcoma (100 patients), melanoma (278 patients), prostate cancer (144 patients), glioma (163 patients). (Tables 1, 2)
### TABLE 1 | Characteristics of studies in this meta-analysis.

| First author | Year | Country | No. of patient | Cancer Type | Method | Cut-off | Outcome | U/M | Analysis | NOS |
|--------------|------|---------|----------------|-------------|--------|---------|---------|-----|----------|-----|
| Ng et al     | 2006 | China   | 103            | Hepatocellular Carcinoma | qPCR | ≥median | OS      | U/M | K-M curve | 8   |
| Kong et al   | 2014 | China   | 284            | Hepatocellular Carcinoma | qPCR | ≥median | OS, DFS | U/M | K-M curve | 9   |
| Chen et al   | 2019 | China   | 23             | Hepatocellular Carcinoma | qPCR | ≥median | OS, DFS | U/M | K-M curve | 8   |
| Ono et al    | 2012 | Japan   | 120            | Colorectal cancer | qPCR | ≥median | OS      | U/M | K-M curve | 7   |
| Kahler et al | 2015 | Germany | 945            | Colorectal cancer | qPCR | ≥median | OS, DFS | U/M | K-M curve | 7   |
| Haidan et al | 2014 | China   | 262            | Breast cancer | qPCR | ≥median | OS, DFS | U/M | K-M curve | 8   |
| Hennessy et al | 2009 | USA     | 89             | Breast cancer | qPCR | −       | OS      | −   | Reported  | 9   |
| Pavitan et al | 2005 | Sweden  | 159            | Breast cancer | qPCR | −       | OS      | −   | Reported  | 8   |
| Bili et al   | 2006 | USA     | 158            | Breast cancer | qPCR | ≥median | OS      | −   | Reported  | 9   |
| Desmedt (1) et al | 2007 | Belgium | 198            | Breast cancer | qPCR | −       | OS      | −   | Reported  | 9   |
| Desmedt (2) et al | 2011 | Belgium | 120            | Breast cancer | qPCR | ≥median | OS      | −   | Reported  | 8   |
| Kao et al    | 2011 | Taiwan  | 327            | Breast cancer | qPCR | ≥median | OS      | −   | Reported  | 9   |
| Dedeurwaerder et al | 2011 | Belgium | 88             | Breast cancer | qPCR | −       | OS      | −   | Reported  | 8   |
| Heikkinen et al | 2011 | Finland | 183            | Breast cancer | qPCR | ≥median | OS      | −   | Reported  | 8   |
| Terunen et al | 2014 | USA     | 61             | Breast cancer | qPCR | ≥median | OS      | −   | Reported  | 9   |
| Nishimura et al | 2017 | Japan   | 60             | Esophageal squamous cell carcinoma | qPCR | ≥median | OS, DFS | U/M | K-M curve | 7   |
| Wei et al    | 2013 | China   | 292            | Esophageal squamous cell carcinoma | qPCR | ≥median | OS      | −   | K-M curve | 7   |
| He et al     | 2017 | China   | 119            | Esophageal squamous cell carcinoma | IHC | ≥median | OS, DFS | U/M | K-M curve | 7   |
| Du et al     | 2017 | China   | 40             | Gastric cancer | IHC | ≥median | OS      | −   | K-M curve | 7   |
| Xie et al    | 2018 | China   | 208            | Gastric cancer | IHC | ≥median | OS, DFS | U/M | K-M curve | 7   |
| Lv et al     | 2014 | China   | 163            | Gastric adenocarcinoma | IHC | ≥median | OS      | −   | K-M curve | 9   |
| Jin et al    | 2014 | China   | 148            | Pancreatic ductal cancer | IHC | ≥median | OS      | −   | K-M curve | 7   |
| Mimae et al  | 2011 | Japan   | 64             | Lung Adenocarcinoma | qPCR | ≥median | OS      | −   | K-M curve | 9   |
| Chao et al   | 2017 | China   | 100            | Osteosarcoma | IHC | ≥median | OS, DFS | U/M | K-M curve | 8   |
| Montero et al | 2019 | Germany | 278            | Melanoma | qPCR | ≥median | OS      | −   | K-M curve | 9   |
| Zeng et al   | 2015 | China   | 144            | Prostate cancer | IHC | ≥median | OS      | −   | K-M curve | 7   |
| Zhang et al  | 2017 | China   | 163            | Glioma | IHC | ≥median | OS      | −   | K-M curve | 7   |

**IHC**, Immunohistochemistry; **OS**, Overall Survival; **DFS**, Disease-free Survival; **NOS**, Newcastle-Ottawa Scale; **U/M**, Univariate/Multivariate survival analysis; **K-M curve**, Kaplan-Meier survival curve; ‘’—’’, Not available/not reported.

### TABLE 2 | Subgroup analysis of pooled HR for OS.

| Categories                                      | Number of studies | Number of patients | Pooled HR (95%CI) | Heterogeneity |
|------------------------------------------------|-------------------|--------------------|-------------------|--------------|
| **All studies**                                 | 27                | 4899               | 1.54 (1.32, 1.80) | <0.00001     | 63           | <0.00001 |
| **Cancer types**                                |                   |                    |                   |              |              |           |
| Hepatocellular Carcinoma                        | 3                 | 410                | 1.50 (1.17, 1.93) | 0.0004       | 75           | 0.003    |
| Colorectal cancer                               | 2                 | 1065               | 2.03 (0.70, 5.84) | 0.19         | 63           | 0.1      |
| Esophageal squamous cell carcinoma              | 3                 | 471                | 1.89 (1.42, 2.52) | <0.00001     | 0            | 0.66     |
| Gastric cancer                                  | 3                 | 411                | 1.66 (0.88, 3.14) | 0.12         | 90           | <0.00001 |
| Breast cancer                                   | 10                | 1645               | 1.31 (1.10, 1.55) | 0.002        | 0            | 0.98     |
| Other cancer types                              | 6                 | 897                | 1.72 (1.07, 2.79) | 0.03         | 86           | <0.00001 |
| **HR estimation**                               |                   |                    |                   |              |              |           |
| Multivariate analysis                           | 16                | 2917               | 1.69 (1.26, 2.27) | 0.0005       | 80           | <0.00001 |
| Univariate analysis                             | 11                | 2812               | 1.90 (1.48, 2.42) | <0.00001     | 66           | 0.001    |
| **Method**                                      |                   |                    |                   |              |              |           |
| qPCR                                            | 13                | 1633               | 1.46 (1.25, 1.70) | <0.00001     | 0            | 0.79     |
| IHC                                             | 14                | 3266               | 1.67 (1.31, 2.14) | <0.00001     | 79           | <0.00001 |
| **Cut off value**                               |                   |                    |                   |              |              |           |
| ≥median                                         | 11                | 1911               | 1.29 (1.05, 1.60) | 0.02         | 49           | 0.02     |
| scores of 4 (≥26% of tumor cells)               | 11                | 2768               | 1.81 (1.43, 2.30) | <0.00001     | 68           | 0.0006   |
| other                                           | 2                 | 220                | 1.80 (1.12, 2.90) | 0.01         | 66           | 0.08     |
| **Ethnicity**                                   |                   |                    |                   |              |              |           |
| Asian                                           | 17                | 2620               | 1.69 (1.45, 1.98) | 0.001        | 59           | <0.00001 |
| European                                        | 7                 | 1971               | 1.01 (0.80, 1.29) | 0.91         | 64           | 0.01     |
| North American                                  | 3                 | 308                | 1.30 (0.86, 1.98) | 0.42         | 0            | 0.96     |

**OS**, overall survival; **DFS**, Disease-free Survival; **IHC**, Immunohistochemistry; **HR**, hazard ratio.
Study Methodology and Study Quality Assessment

The technical detail and the study methodology for SIX1 protein quantification is also shown in Table 1. There were 14 studies that analyzed SIX1 mRNA expression using qPCR and 13 studies that quantified tumor protein expression by using IHC. We did not identify any study that quantified SIX1 protein expression level in tumor lysate. Most of the studies analyzed the expression of other factors with SIX1 simultaneously, found in 20 studies (Table 1).

Survival Analysis

The pooled HR for overall survival in patients with high SIX1 expression compared with low expression was 1.54 (95% CI: 1.32, 1.81).

The method for defining low and high SIX1 expression level was reported in 89% of studies, with 33% of studies defined high SIX1 expression as above median value, 40% of studies based on IHC scores (≥ 26% positive cells), only one of the studies determining SIX1 value cutoffs based on ROC curve analysis.
1.32-1.80, P<0.00001), but with a significant degree of heterogeneity ($I^2 = 63\%$) (Figure 2A), while the pooled HR for disease-free survival was 1.83 (95% CI: 1.31-2.55, $P=0.0004$), again with a high degree of study heterogeneity ($I^2 = 75\%$) (Figure 2B). Funnel plots for overall, disease-free survival demonstrated no evidence of publication bias or small study effects (Figure 2C). The major cause of the heterogeneity was because of the relationship between SIX1 expression and the outcome of osteosarcoma.

**Subgroup Analysis**

The subgroup analysis showed that the SIX1 expression is associated with reduced overall survival in hepatocellular carcinoma (HR 1.50; 95% CI: 1.17-1.93, $P=0.001$), Esophageal squamous cell carcinoma (HR 1.89; 95% CI: 1.42-2.52, $P<0.0001$) and breast cancer (HR 1.31; 95% CI: 1.10-1.55, $P=0.002$). (Table 2 and Figure 3) For colorectal and gastric cancer, however, there was no relationship between SIX1 expression and overall survival (HR 2.03; 95% CI: 0.70-5.84, $P=0.19$) and (HR 1.66; 95% CI: 0.88-3.15, $P=0.12$), respectively.

We further performed subgroup analyses based on defining SIX1 expression method, reasoning that this analysis might help differentiate the studies with high level of heterogeneity (Table 2).

**SIX1 Overexpression Level and Its Relative Clinical Parameters**

To evaluate SIX1 precisely of its impact on clinical outcome, we investigated the correlations between SIX1 expression level and the clinical parameters with included cancers (Table 3). We found that the expression levels of SIX1 was related with the histological grade (HR=2.00, 95% CI=1.04, 3.86, $P=0.04$), tumor size (HR=2.11, 95% CI=1.22, 3.65, $P=0.007$), lymph node metastasis (HR=1.97, 95% CI=1.32, 2.93, $P=0.0008$), clinical stage (HR=3.34, 95% CI=1.86, 5.98, $P<0.0001$), TNM stage (HR = 3.87, 95% CI = 2.03, 7.39, $P<0.0001$), significantly. While there were no significant associations between SIX1 expression and gender, age, distant metastasis. These correlations indicated that SIX1 high expression was associated with the malignant biological behaviors in cancers (Table 3).

**Sensitivity Analysis and the Publication Bias Evaluation**

We performed sensitivity analysis to analyze whether a single study could affect the overall result. Results showed that the associated studies between SIX1 expression and OS and DFS demonstrated that the single study cannot influence the result of meta-analysis (Figures 4A, B). Begg’s test and Egger’s test were used, and showed there is no publication bias existed in the studies on associations between SIX1 overexpression level and OS ($P = 0.497$), DFS ($P = 0.940$) (Figures 4C, D).

**SIX1 Expression Data and the TCGA Online Datasets**

The SIX1 expression level in various tumors were performed by GEPIA, a public online database that provide customized survey based on TCGA and GTEx datasets. SIX1 expression is detected in 13 types of cancers and demonstrated that SIX1 expression is significantly higher in cancer tissues than in the normal tissues (Figure 5A). Besides, we found in Testicular germ cell tumor (TGCT) and Thyroid carcinoma (THCA) the SIX1 expression is inversely downregulated, which are not included in our meta-analysis (Figure 5B).

**Validation of Prognostic Correlations in TCGA Online Datasets**

To validate the clinical prognosis value of SIX1, we explored TCGA datasets by KM-plotter, an interactive online tool that analyze the expression data of genes based on TCGA. The significant association between high SIX1 expression and poor OS was found in 9 types of cancers (Figure 6). The result of our meta-analysis and TCGA datasets validation demonstrated the correlation between the SIX1 expression level and the breast cancer, liver hepatocellular carcinoma. The OS data of the other seven cancer types were provided for additional information.

**PPI Network and Functional Enrichment Analysis**

To further analyze the molecular mechanisms of SIX1, we generate PPI networks of SIX1-related genes obtained by STRING, totally observed 10 nodes and 23 edges (Supplementary Figure 1A). SIX1-related genes were collected for biological functional enrichment analysis (Supplementary Figure 1B). The top significant terms, contained the biological processes, cell components and molecular function, and the most significant were selected. These SIX1-related genes were significantly enriched in DNA binding, catalytic activity, and transcription binding.

**DISCUSSION**

Recently, increased evidence indicated that SIX1 is involved in multiple process of tumor development and indicated the expression level of SIX1 could be a biomarker for assessing the prognosis in tumors. However, limited by insufficient data and complicated experimental model, single study usually meets the restrictions easily, and the data is unreliable. Therefore, a meta-analysis based on pooled studies is necessary for discovering the potential clinical value of SIX1 expression and the correlation in cancer patient prognosis.

The primary aim of this meta-analysis is to determine whether SIX1 is associated with survival outcome in cancer patients. We discovered that high SIX1 expression is associated with poorer overall survival in patients with breast cancer, hepatocellular carcinoma, and Esophageal squamous cell carcinoma. Our data indicated that SIX1 levels is helpful for predicting patient’s prognosis in these cancer types. Although some studies invalid SIX expression analysis studies were excluded from our study pool, some published studies that assessed SIX1 mRNA level based on TCGA datasets supported
**FIGURE 3** Forest plot of subgroup analysis by cancer type and OS.

**Colorectal cancer**

| Study or Subgroup | log[Hazard Ratio] | SE | Weight | Hazard Ratio IV, Random, 95% CI | Year |
|-------------------|-------------------|----|--------|---------------------------------|------|
| Ono et al         | 0.2937            | 0.2561 | 63.1% | 1.34 [0.81, 2.22]               | 2012 |
| Kahlert et al     | 1.4132            | 0.628   | 36.9% | 4.11 [1.20, 14.07]              | 2015 |

Total (95% CI) 100.0% 2.03 [0.70, 5.84]

Heterogeneity: Tau² = 0.40; Chi² = 2.72; df = 1 (P = 0.10); I² = 63%

Test for overall effect: Z = 1.31 (P = 0.19)

**Hepatocellular carcinoma**

| Study or Subgroup | log[Hazard Ratio] | SE | Weight | Hazard Ratio IV, Random, 95% CI | Year |
|-------------------|-------------------|----|--------|---------------------------------|------|
| Ng et al          | 0.2229            | 0.3544 | 13.1% | 1.25 [0.62, 2.50]               | 2006 |
| Kong et al        | 0.491             | 0.2213 | 33.6% | 1.63 [1.06, 2.52]               | 2014 |
| Chen et al        | 0.4025            | 0.1756 | 53.3% | 1.50 [1.06, 2.11]               | 2019 |

Total (95% CI) 100.0% 1.50 [1.17, 1.93]

Heterogeneity: Tau² = 0.00; Chi² = 0.41; df = 2 (P = 0.81); I² = 0%

Test for overall effect: Z = 3.19 (P = 0.001)

**Breast cancer**

| Study or Subgroup | log[Hazard Ratio] | SE | Weight | Hazard Ratio IV, Random, 95% CI | Year |
|-------------------|-------------------|----|--------|---------------------------------|------|
| Pawitan et al     | 0.1262            | 0.3168 | 7.5%  | 1.13 [0.81, 1.51]               | 2005 |
| Bland et al       | 0.3072            | 0.2835 | 8.3%  | 1.36 [0.78, 2.37]               | 2006 |
| Desmedt et al     | 0.5308            | 0.2759 | 8.6%  | 1.70 [0.99, 2.92]               | 2007 |
| Hennessy et al    | 0.2992            | 0.5271 | 2.7%  | 1.35 [0.48, 3.79]               | 2009 |
| Heikkinen et al   | -0.1337           | 0.3624 | 5.7%  | 0.87 [0.43, 1.78]               | 2011 |
| Kao et al         | 0.2004            | 0.2225 | 15.1% | 1.22 [0.79, 1.89]               | 2011 |
| Dedererander et al| 0.2988            | 0.4047 | 4.6%  | 1.35 [0.61, 2.98]               | 2011 |
| Desmedt et al (2) | 0.3453            | 0.5298 | 2.7%  | 1.41 [0.50, 3.99]               | 2014 |
| Terunuma et al    | 0.1584            | 0.4047 | 4.6%  | 1.17 [0.53, 2.59]               | 2014 |
| Haidar et al      | 0.3034            | 0.1402 | 38.1% | 1.35 [1.03, 1.78]               | 2014 |

Total (95% CI) 100.0% 1.31 [1.10, 1.55]

Heterogeneity: Tau² = 0.00; Chi² = 2.62; df = 9 (P = 0.98); I² = 0%

Test for overall effect: Z = 3.06 (P = 0.003)

**Esophageal squamous carcinoma**

| Study or Subgroup | log[Hazard Ratio] | SE | Weight | Hazard Ratio IV, Random, 95% CI | Year |
|-------------------|-------------------|----|--------|---------------------------------|------|
| Wei et al         | 0.931             | 0.3673 | 15.9% | 2.94 [1.24, 5.21]               | 2013 |
| He et al          | 0.6259            | 0.2336 | 39.2% | 1.87 [1.18, 2.96]               | 2017 |
| Nishimura et al   | 0.544             | 0.2163 | 44.9% | 1.72 [1.12, 2.64]               | 2017 |

Total (95% CI) 100.0% 1.89 [1.42, 2.52]

Heterogeneity: Tau² = 0.00; Chi² = 0.82; df = 2 (P = 0.66); I² = 0%

Test for overall effect: Z = 4.36 (P = 0.0001)

**Gastric cancer**

| Study or Subgroup | log[Hazard Ratio] | SE | Weight | Hazard Ratio IV, Random, 95% CI | Year |
|-------------------|-------------------|----|--------|---------------------------------|------|
| Lv et al          | 1.2748            | 0.2215 | 31.6% | 3.58 [2.32, 5.52]               | 2014 |
| Du et al          | 0.2546            | 0.1090 | 35.8% | 1.29 [1.04, 1.60]               | 2017 |
| Xie et al         | 0.83              | 0.2076 | 32.4% | 1.03 [0.69, 1.55]               | 2018 |

Total (95% CI) 100.0% 1.66 [0.88, 3.15]

Heterogeneity: Tau² = 0.29; Chi² = 20.46; df = 2 (P < 0.0001); I² = 0%

Test for overall effect: Z = 1.55 (P = 0.12)

**Other cancers**

| Study or Subgroup | log[Hazard Ratio] | SE | Weight | Hazard Ratio IV, Random, 95% CI | Year |
|-------------------|-------------------|----|--------|---------------------------------|------|
| Minna et al       | 0.7838            | 0.2282 | 17.6% | 2.10 [1.40, 3.42]               | 2011 |
| Jin et al         | 0.7715            | 0.2293 | 17.6% | 2.16 [1.38, 3.39]               | 2014 |
| Zeng et al        | 1.2339            | 0.5003 | 10.2% | 3.43 [1.17, 10.10]              | 2015 |
| Zhang et al       | 0.5131            | 0.2562 | 18.9% | 1.67 [1.01, 2.79]               | 2017 |
| Chao et al        | 0.7887            | 0.1296 | 19.6% | 2.20 [1.71, 2.84]               | 2017 |
| Monteiro et al    | -0.5257           | 0.2018 | 18.2% | 0.59 [0.40, 0.88]               | 2019 |

Total (95% CI) 100.0% 1.72 [1.07, 2.79]

Heterogeneity: Tau² = 0.26; Chi² = 35.33; df = 5 (P < 0.0001); I² = 66%

Test for overall effect: Z = 2.22 (P = 0.03)
our findings, indicating that SIX1 aberrant expression and poor patient prognosis in sarcoma, but we failed to find relative articles for further analyze.

Our second purpose is to discover whether SIX1 can be used as a prognostic biomarker in cancer patients. This requires large quantity of clinical samples and be carefully analyzed. Most of the studies included were of a prospective and retrospective, some were purely retrospective. These may result in a risk of bias. The bias is reassured by the funnel plots, extracted data from studies that reporting overall and disease-free survival, also demonstrated no evidence of publication bias. Both results were supported by both Begg’s funnel plots and Egger’s plots. This suggests that the nonsignificant findings associated between SIX1, and outcome are somehow published frequently and lower the inaccuracy of our analysis.

For being a helpful prognostic biomarker, SIX1 must display clinical utility, analytic and clinical validity. For studies that meet the included criteria, the SIX1 potential clinical validity is examined in the ‘subgroups’ analysis. Clinicopathological features analysis displayed that the SIX1 overexpression was linked with poor histological grade, tumor size, venous infiltration, lymph node metastasis, late clinical stages and advanced TNM stages. These data indicated that there is a correlation between SIX1 expression and advanced cancer features. Subgroup analysis based on cancer types showed the associations between overexpressed SIX1 and poor overall OS in
TABLE 3 | Clinicopathological features and the high expressed SIX1 in patients with cancer.

| Clinicopathological parameters                          | Number of studies | Number of patients | Model  | Risk of high SIX1 OR 95%CI | Significant Z | p-value | Heterogeneity |
|----------------------------------------------------------|-------------------|--------------------|--------|-----------------------------|---------------|---------|---------------|
| Gender (Male vs. Female)                                 | 14                | 2484               | Fixed  | 0.99 (0.83, 1.18)           | 0.1           | 0.92    | 40            |
| Age                                                      |                   |                    |        |                             |               |         |               |
| >25 vs. ≤25                                              | 1                 | 100                | —      | 0.90 (0.40-2.01)            | —             | 0.80    | —             |
| >45 vs. ≤45                                              | 1                 | 160                | —      | 0.66 (0.25-1.74)            | —             | 0.40    | —             |
| >50 vs. ≤50                                              | 6                 | 1055               | Fixed  | 0.97 (0.74, 1.27)           | 0.24          | 0.81    | 17.0          |
| >55 vs. ≤55                                              | 1                 | 103                | —      | 1.168 (0.53-2.60)           | —             | 0.70    | —             |
| >60 vs. ≤60                                              | 3                 | 322                | Fixed  | 1.09 (0.69, 1.73)           | 0.37          | 0.71    | 0             |
| >65 vs. ≤65                                              | 1                 | 144                | —      | 1.09 (0.57-2.11)           | —             | 0.79    | —             |
| Histological grade (poor vs. well and moderate)          | 9                 | 2320               | Random | 2.00 (1.04, 3.86)           | 2.07          | 0.04    | 88            |
| Tumor size (large vs. small)                             | 9                 | 1248               | Random | 2.11 (1.22, 3.65)           | 2.68          | 0.007   | 70            |
| Venous infiltration (present vs. absent)                 | 2                 | 265                | Random | 6.89 (3.82, 12.42)         | 6.41          | 0.02    | 83            |
| Lymph node metastasis (positive vs. negative)            | 9                 | 2155               | Random | 1.97 (1.32, 2.93)           | 3.34          | 0.0008  | 67            |
| Distant metastasis (positive vs. negative)               | 4                 | 562                | Fixed  | 1.36 (0.83, 2.21)           | 1.23          | 0.22    | 0             |
| Clinical stage (late vs. early)                          | 10                | 2271               | Random | 3.34 (1.86, 5.98)           | 4.04          | <0.0001 | 84            |
| TNM stage (III, IV vs. I, II)                            | 5                 | 632                | Random | 3.87 (2.03, 7.39)           | 4.1           | <0.0001 | 63            |
| Recurrence (Yes vs. No)                                  | 7                 | 1469               | Fixed  | 1.39 (1.13, 1.72)           | 3.11          | 0.002   | 0             |
| Other effects (positive vs. negative)                    |                   |                    |        |                             |               |         |               |
| AFP (20ng/ml)                                            | 2                 | 265                | Random | 1.13 (0.52, 2.48)           | 0.3           | 0.76    | 55            |
| HBsAg status                                             | 2                 | 264                | Random | 0.83 (0.27, 2.55)           | 0.33          | 0.74    | 61            |
| ER                                                       | 5                 | 698                | Fixed  | 0.88 (0.64, 1.21)           | 0.79          | 0.43    | 33            |
| PR                                                       | 2                 | 351                | Fixed  | 1.26 (0.80, 1.99)           | 0.98          | 0.33    | 4             |
| Basal/Luminal                                            | 5                 | 724                | Fixed  | 0.44 (0.29, 0.68)           | 3.75          | 0.0002  | 0             |

OR, Odds ratio; AFP, alpha fetoprotein; ER, Estrogen receptors; PR, Progesterone receptors.

cancer patients. SIX1 is significative in the hepatocellular carcinoma, Esophageal squamous cell carcinoma, and breast cancer, but not in the colorectal cancer and gastric cancer. This was also verified by TCGA online database and displayed in KM curves in Figure 6.

We next evaluated the SIX1 expression and its impact on clinical outcome different clinical parameters were included. Expression levels of SIX1 was related with the histological grade, tumor size, lymph node metastasis, clinical stage, TNM stage, significantly. These data indicated SIX1 is associated with tumorigenesis and tumor growth, accelerates tumor progression. This may also give images on SIX1 is essential in cancer cell proliferation, for SIX1, in another point of view, plays key roles in embryonic development and cell growth. Though there were no significant associations between SIX1 expression gender, age, and distant metastasis, we found that SIX1 has its roles in lymph node metastasis, clinical stage and TNM stage. We believe that SIX1 is an important regulator in cancer cell metastasis, but the result showed that SIX1 is unrelated with distant metastasis may be due to lacing of clinical samples and the refractory of late staged cancer patients carrying distant metastasis.

Although, SIX1 was found highly expressed in various malignancies and was related to a more aggressive phenotype, late clinical stage, and poor prognosis. The exact mechanisms of how SIX1 promotes tumorigenesis remains unclear (2). The gene functional enrichment analysis showed that SIX1 is a critical transcription factor in tumorigenesis, SIX1 related genes significantly enriched in DNA, E-box binding and DNA transcription regulation. Reports shown that SIX1 overexpression activate breast cancer cell proliferation and tumorigenesis by activating cyclin A1 transcription directly (47). In 2006, Ng et al. demonstrated that SIX1 is significantly associated with the recurrence and metastasis of HCC and SIX1 miRNA overexpression was observed in 85% of the HCC (21). This molecule is also involved in the Epithelial-to-mesenchymal transition (EMT) and was described as its activation of ZEB1 transcription and TGF-β signaling regulation, both found in colorectal and cervical cancer (48, 49).

The data displayed in this study only provided limited information about the clinical utility of SIX1 and were in specific groups of cancer patients. This might because of the failure of some of the included studies did not provide adequately the numbers of the cancer patients. We found that even some basic data such as age, sex, clinical features like tumor size, tumor stage was not always recorded. Future studies therefore better determine and report the analysis clearly in a subset of cancer patients with the basis of histopathological and clinical utility of SIX1 expression (50, 51). Hence, addition of the online datasets supplement provides a more convinced display.

In summary, this meta-analysis used multiple search strategies identified a wide range of studies from different populations, clinical parameters-based subgroup analysis and highlighted the potential differences in each relationship associated with SIX1 expression and the prognosis in various cancer types. This systematical assessment, we believe will perform a guidance, and it will ensure the improvement of higher quality treatment data in the SIX1 investigations as a prognostic biomarker. There also require balances of the facts.
FIGURE 5 | TCGA data sets represent SIX1 aberrant expression levels in various cancer types. (A). SIX1 overexpressed cancer types; (B). SIX1 lower expressed cancer types. * means P value < 0.05 have statistical significance.
that some included criteria failed to blind the assessor on SIX1 and the outcome status evaluation may lead to a risk of reporter bias. Overall, the quality of this study still needs improvement, and more progress is needed to make a better defining of SIX1 expression and its roles in cancers.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.
AUTHOR CONTRIBUTIONS

YP and ZL helped analyze the data. GZ drafted and write the paper. YL and LZ revised the article. All authors contributed to the article and approved the submitted version.

FUNDING

This work was supported by the Funds for Local Science and Technology Development Guided by the Central Committee, basic research project of Jilin Province.

REFERENCES

1. Global Burden of Disease Cancer C, Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol (2019) 5(12):1749–68. doi: 10.1001/jamaoncol.2019.2996

2. Wu W, Ren Z, Li P, Yu D, Chen J, Huang R, et al. SIX1: A Critical Transcription Factor in Tumorigenesis. Int J Cancer (2015) 136:1245–53. doi: 10.1002/ijc.28755

3. Wu W, Huang R, Wu Q, Li P, Chen J, Li B, et al. The Role of SIX1 in the Genesis of Muscle Cell and Skeletal Muscle Development. Int J Biol Sci (2014) 10:983–9. doi: 10.7150/ijbs.9442. eCollection 2014.

4. Yu J, McMahon AP, Valerius MT. Recent Genetic Studies of Mouse Kidney Development. Curr Opin Genet Dev (2004) 14:550–7. doi: 10.1016/j.gde.2004.07.009

5. Sato S, Furuta Y, Kawakami K. Regulation of Continuous But Complex Expression Pattern of SIX1 During Early Sensory Development. Dev Dyn (2018) 247:250–61. doi: 10.1002/dvdy.24603

6. Zhang T, Xu J, Maire P, Xu PX. SIX1 Is Essential for Differentiation and Patterning of the Mammalian Auditory Sensory Epithelium. PLoS Genet (2017) 13:e1006967. doi: 10.1371/journal.pgen.1006967

7. Kong D, Li A, Liu Y, Cui Q, Wang K, Zhang D, et al. SIX1 Activates STAT3 Signaling to Promote the Proliferation of Thyroid Carcinoma via EYA1. Front Oncol (2019) 9:1450. doi: 10.3389/fonc.2019.01450

8. Xu HX, Wu KJ, Tian YJ, Liu Q, Han N, He XL, et al. Expression Profile of SIX Family Members Correlates With Clinic-Pathological Features and Prognosis of Breast Cancer: A Systematic Review and Meta-Analysis. Med (Baltimore) (2016) 95:e4085. doi: 10.1097/MD.0000000000004085

9. Yang Z, Feng Z, Gu J, Li X, Dong Q, Liu K, et al. Microrna-488 Inhibits Chemoresistance of Ovarian Cancer Cells by Targeting the SIX1 Gene Network and Its Role in Tumor Initiation and Progression. Int J Cancer (2016) 138:1067–75. doi: 10.1002/ijc.29560

10. Liu Q, Li A, Tian Y, Liu Y, Li T, Zhang C, et al. The Expression Profile and Clinic Significance of the SIX Family in Non-Small Cell Lung Cancer. J Hematol Oncol (2016) 9:119. doi: 10.1186/s13045-016-0339-1

11. Pan N, Leoncini E, de Belvis G, Ricciardi W, Boccia S. Evaluation of the Endorsement of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Statement on the Quality of Published Systematic Review and Meta-Analyses. PLoS One (2013) 8:e83138. doi: 10.1371/journal.pone.0083138

12. Higgins JP, Flicker L. Lecithin for Dementia and Cognitive Impairment. Cochrane Database Syst Rev (2003) 3:CD001015. doi: 10.1002/14651858.CD001015

13. Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et al. The Methodological Quality Assessment Tools for Preclinical and Clinical Studies, Systematic Review and Meta-Analysis, and Clinical Practice Guideline: A Systematic Review. J Evid Based Med (2015) 8:2–10. doi: 10.1111/jebm.12141

14. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: A Web Server for Cancer and Normal Gene Expression Profiling and Interactive Analyses. Nucleic Acids Res (2017) 45:W98–W102. doi: 10.1093/nar/gkx247

15. Szklarczyk D, Franceschini A, Wyder S, Forslund K, Heller D, Huerta-Cepas J, et al. STRING V10: Protein-Protein Interaction Networks, Integrated Over the Tree of Life. Nucleic Acids Res (2015) 43:447–52. doi: 10.1093/nar/gku003

16. Mimae T, Okada M, Hagiyama M, Miyata Y, Tsutani Y, Inoue T, et al. Attenuating the Stemness of Hepatocellular Carcinoma Cells. J Biomed Biotechnol (2017) 2017:1250158. doi: 10.1155/2017/1250158

17. Tong Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: A Web Server for Cancer and Normal Gene Expression Profiling and Interactive Analyses. Nucleic Acids Res (2017) 45:W98–W102. doi: 10.1093/nar/gkx247

18. Higgins JP, Flicker L. Lecithin for Dementia and Cognitive Impairment. Cochrane Database Syst Rev (2003) 3:CD001015. doi: 10.1002/14651858.CD001015

19. Zeng X, Zhang Y, Kwong JS, Zhang C, Li S, Sun F, et al. The Methodological Quality Assessment Tools for Preclinical and Clinical Studies, Systematic Review and Meta-Analysis, and Clinical Practice Guideline: A Systematic Review. J Evid Based Med (2015) 8:2–10. doi: 10.1111/jebm.12141

20. Cui X, Wang K, Zhang D, et al. STRING V10: Protein-Protein Interaction Networks, Integrated Over the Tree of Life. Nucleic Acids Res (2015) 43:447–52. doi: 10.1093/nar/gku003

21. Mimae T, Okada M, Hagiyama M, Miyata Y, Tsutani Y, Inoue T, et al. Attenuating the Stemness of Hepatocellular Carcinoma Cells. J Biomed Biotechnol (2017) 2017:1250158. doi: 10.1155/2017/1250158

22. Tong Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: A Web Server for Cancer and Normal Gene Expression Profiling and Interactive Analyses. Nucleic Acids Res (2017) 45:W98–W102. doi: 10.1093/nar/gkx247

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.622331/full/supplementary-material

SUPPLEMENTARY Figure 1 | Mechanisms prediction of SIX1-related genes with bioinformatics and enrichment. (A) The protein-protein interaction network of SIX1-related genes. (B) The functional enrichment analysis of SIX1-related genes.
29. Kuhlert C, Lerbs T, Pecequeux M, Herpel E, Hoffmeister M, Jansen L, et al. Overexpression of SIX1 Is an Independent Prognostic Marker in Stage I-III Colorectal Cancer. Int J Cancer (2015) 137:2104–13. doi: 10.1002/ijc.29596
30. Zeng J, Shi R, Cai CX, Liu XR, Song YB, Wei M, et al. Increased Expression of SIX1 Correlates With Progression and Prognosis of Prostate Cancer. Cancer Cell Int (2015) 15:63. doi: 10.1186/s12935-015-0215-z
31. Jin H, Cui M, Kong J, Cui X, Lin Z, Wu Q, et al. Sineoculis Homeobox Homolog 1 Protein Is Associated With Breast Cancer Progression and Survival Outcome. Exp Mol Pathol (2014) 97:247–52. doi: 10.1016/j.yexmp.2014.07.005
32. Zhang X, Xu R. SIX1 Expression Is Associated With a Poor Prognosis in Patients With Glioma. Oncol Lett (2017) 13:1293–8. doi: 10.3892/ol.2017.5577
33. Nishimura T, Tamaoki M, Komatsuzaki R, Oue N, Taniyuchi H, Komatsu M, et al. SIX1 Maintains Tumor Basal Cells via Transforming Growth Factor-Beta Pathway and Associates With Poor Prognosis in Esophageal Cancer. Cancer Sci (2017) 108:216–25. doi: 10.1111/cas.13135
34. Wei Q, Yu WW, Zhao KL, Fu XL, Zhu ZF, Qin GQ, et al. Expression of SIX1 and SIX4 in Esophageal Squamous Cell Carcinoma and Their Correlation With Clinical Prognosis. Zhonghua Bing Li Xue Za Zhi (2013) 42:446–50. doi: 10.3760/cma.j.issn.0529-5807.2013.07.004
35. He Z, Li G, Tang L, Li Y. SIX1 Overexpression Predicts Poor Prognosis and Induces Radioresistance Through AKT Signaling in Esophageal Squamous Cell Carcinoma. Onco Targets Ther (2017) 10:1071–9. doi: 10.2147/OTT.S125330
36. Xie Y, Jin P, Sun X, Jiao T, Zhang Y, Li Y, et al. SIX1 Is Upregulated in Gastric Cancer and Determines Replication and Invasion by Targeting the ERK Pathway and Promoting Epithelial-Mesenchymal Transition. Cell Biochem Funct (2018) 36:413–9. doi: 10.1002/cbf.3361
37. Du P, Zhao J, Wang J, Liu Y, Ren H, Patel R, et al. Sine Oculis Homeobox Homolog 1 Regulates Mitochondrial Apoptosis Pathway via Caspase-7 in Gastric Cancer Cells. J Cancer (2017) 8:436–45. doi: 10.7150/jca.16018
38. Lv H, Cui A, Sun F, Zhang Y, Li Y, Li L, et al. Sineoculis Homeobox Homolog 1 Protein as an Independent Biomarker for Gastric Adenocarcinoma. Exp Mol Pathol (2014) 97:74–80. doi: 10.1016/j.yexmp.2014.05.007
39. Jin A, Xu Y, Liu S, Jin T, Li Z, Jin H, et al. Sineoculis Homeobox Homolog 1 Protein Overexpression as an Independent Biomarker for Pancreatic Ductal Adenocarcinoma. Exp Mol Pathol (2014) 96:54–60. doi: 10.1016/j.yexmp.2013.11.003
40. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, et al. Characterization of a Naturally Occurring Breast Cancer Subset Enriched in Epithelial-to-Mesenchymal Transition and Stem Cell Characteristics. Cancer Res (2009) 69:4116–24. doi: 10.1158/0008-5472.CAN-08-3441
41. Pavitan Y, Bjølke J, Amler L, Borgia AL, Eghazai S, Hall P, et al. Gene Expression Profiling Spares Early Breast Cancer Patients From Adjuvant Therapy: Derived and Validated in Two Population-Based Cohorts. Breast Cancer Res (2005) 7:R93–964. doi: 10.1186/bcr1325
42. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic Pathway Signatures in Human Cancers as a Guide to Targeted Therapies. Nature (2006) 439:353–7. doi: 10.1038/nature04296
43. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, et al. Strong Time Dependence of the 76-Gene Prognostic Signature for Node-Negative Breast Cancer Patients in the TRANSBIG Multicenter Independent Validation Series. Clin Cancer Res (2007) 13:3207–14. doi: 10.1158/1078-0432.CCR-06-2765
44. Desmedt C, Di Leo A, de Azambuja E, Larssimon D, Haibe-Kains B, Selleslægs J, et al. Multifactorial Approach to Predicting Resistance to Anthracyclines. J Clin Oncol (2011) 29:1578–86. doi: 10.1200/JCO.2010.31.2231
45. Kao KJ, Chang KM, Hsu HC, Huang AT. Correlation of Microarray-Based Breast Cancer Molecular Subtypes and Clinical Outcomes: Implications for Treatment Optimization. BMC Cancer (2011) 11:143. doi: 10.1186/1471-2407-11-143
46. Dedeuwaerde S, Desmedt C, Calonne E, Singhal SK, Haibe-Kains B, Deffrance M, et al. DNA Methylation Profiling Reveals a Predominant Immune Component in Breast Cancers. EMBO Mol Med (2011) 3:726–41. doi: 10.1002/emmm.201100801
47. Heikkinen T, Greco D, Pelttari LM, Tommiska J, Vaheri P, Heikkila P, et al. Variants on the Promoter Region of PTEN Affect Breast Cancer Progression and Patient Survival. Breast Cancer Res (2011) 13:130. doi: 10.1186/bcr3076
48. Terunuma A, Putluri N, Mishra P, Mathe E, A Dorsey TH, Yi M, et al. MYC-Driven Accumulation of 2-Hydroxyglutarate Is Associated With Breast Cancer Prognosis. J Clin Invest (2014) 124:398–412. doi: 10.1172/JCI71180
49. Christensen KL, Brennan JD, Aldridge CS, Ford HL. Cell Cycle Regulation of the Human SIX1 Homeoprotein Is Mediated by APC(G611). Oncogene (2007) 26:406–41. doi: 10.1038/sj.onc.1210122
50. Lee MY, Shen MR. Epithelial-Mesenchymal Transition in Cervical Carcinoma. Am J Transl Res (2012) 4:1–13.
51. Farabaugh SM, Micalizzi DS, Jedlicka P, Zhao R, Ford HL. Eya2 Is Required to Mediate the Pro-Metastatic Functions of SIX1 via the Induction of TGF-Beta Signaling, Epithelial-Mesenchymal Transition, and Cancer Stem Cell Properties. Oncogene (2012) 31:552–62. doi: 10.1038/onc.2011.259

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Zhu, Liu, Zhao, Lin and Piao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.